Mesa Laboratories, Inc. (MLAB) Stock Price & Analysis
Mesa Laboratories, Inc. (MLAB) closed at USD 128.66 on Friday, October 23, 2026, down 0.34% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 128.66; the Oct 23, 2026 session ranged USD 125.14–129.62 on volume of 88,253 shares. Market capitalization is —, with a 52-week range of USD 69.51–144.35 (NMS). Source: Nexqual, retrieved October 24, 2026 at 03:02 UTC.
Also available as compact Markdown for AI agents: nexqual.com/MLAB.md
Key facts (MLAB)
- Last four reported quarters (through Jun 30, 2026): revenue $250M, net income $4.8M (1.9% margin), free cash flow $52.9M (SEC filings).
- Insider open-market sales, last ~7 months: 7 Form 4 filings, $1.6M; 3 not under a Rule 10b5-1 plan ($1.1M); 2 by opportunistic insiders (1 outside 10b5-1 plans), 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 1 Form 4 filing, $102K; 0 by opportunistic insiders, 0 by routine insiders.
- Total return with dividends: 1Y +63.6% vs S&P 500 +13.4%; 5Y -56.8% vs S&P 500 +76.9%.
- Next earnings: 2026-11-09, EPS estimate USD 2.24, revenue estimate $62.2M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (MLAB)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $184M | $219M | $216M | $241M | $249M | $250M |
| Gross profit | $109M | $134M | $133M | $151M | $158M | — |
| Operating income | $4.7M | $3.3M | -$272M | $16.3M | $18.5M | $22.5M |
| Net income | $1.9M | $930K | -$254M | -$2.0M | $6.7M | $4.8M |
| EPS (diluted) | $0.35 | $0.17 | -$47.20 | -$0.36 | $1.21 | — |
| Free cash flow | $34.8M | $23.4M | $41.6M | $42.6M | $39.6M | $52.9M |
| Gross margin | 59.2% | 61.0% | 61.6% | 62.6% | 63.5% | — |
| Operating margin | 2.6% | 1.5% | -125.9% | 6.8% | 7.4% | 9.0% |
| Net margin | 1.0% | 0.4% | -117.6% | -0.8% | 2.7% | 1.9% |
| Revenue growth | +37.6% | +18.8% | -1.3% | +11.5% | +3.4% | — |
| Cash + short-term investments | $49.3M | $32.9M | $28.2M | $27.3M | $26.9M | — |
| Total debt | $169M | $170M | $171M | $71.3M | $67.5M | — |
Fiscal years end Mar. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (MLAB)
P/E at fiscal year-ends: Mar 2026 73.3x.
Insider sales (SEC Form 4, open-market, last ~7 months) (MLAB)
4 of 7 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-13 | Sullivan John James | Director | 7,093 | $800K | 10.1% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-06-22 | Crennen Lyndsey Elizabeth | CAO | 442 | $40K | 18% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-06-22 | Archbold Brian David | SVP Operations | 2,516 | $225K | 28.3% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-06-22 | Sakys John | CFO | 2,827 | $253K | 12.5% | Yes | Too little history (no open-market trades in 2024) |
| 2026-06-16 | Archbold Brian David | SVP Operations | 1,151 | $117K | 23.7% | Yes | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-06-16 | Crennen Lyndsey Elizabeth | CAO | 118 | $12K | 7.4% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-06-16 | Sakys John | CFO | 1,223 | $124K | 6.9% | Yes | Too little history (no open-market trades in 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Insider purchases (SEC Form 4, open-market, last ~7 months) (MLAB)
1 purchase, $102K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-08-13 | Tripeny R Tony | Director | 900 | $102K | 113.69 | Too little history (no open-market trades in 2023–2025) |
Analysts (MLAB)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-14 | Wells Fargo | Target raised | Equal-Weight | $94 → $110 |
Total return (dividends reinvested) (MLAB)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +63.6% | -56.8% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | +63.8% | -15.5% |
| Volatility (annualized) | 53.5% | 46.8% |
| Max drawdown | -24.2% (Feb 2026→Mar 2026) | -80.9% (Dec 2021→Sep 2025) |
MLAB revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Sterilization & Disinfection Control | $24.5M | 40.7% | -3.6% |
| Calibration Solutions | $13.3M | 22.1% | +7.6% |
| Biopharmaceutical Development | $12.1M | 20.1% | +5.0% |
| Clinical Genomics | $10.3M | 17.1% | -0.1% |
| Total revenue | $60.1M | 100% | — |
MLAB revenue by product line (fiscal year ended Mar 31, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Product | $203.4M | 81.6% | +2.5% |
| Service | $45.7M | 18.4% | +7.4% |
| Total revenue | $249.1M | 100% | — |
MLAB revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $29.7M | 49.5% | +7.6% |
| Other | $25.0M | 41.5% | -5.7% |
| China | $5.4M | 9.0% | +0.1% |
| Total revenue | $60.1M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
MLAB company outlook (results filed Aug 10, 2026)
- “In November, alongside first-half results, I will give full-year guidance," said Siddhartha Kadia, President and CEO of Mesa. "First quarter revenues of $60,138 represented 1.0% organic (0.4% core organic) growth, returning the Company to positive core organic growth in 1Q27 as we stated last quarter.”
- “AOI excluding unusual items was 25.6% of revenues versus 21.7% in 1Q26, above expectations even as we increased investment in SDC to support future organic growth.”
Quoted word-for-word from the SEC 8-K results press release.
MLAB analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $2.24 | $1.26 | +77.8% | $62.2M | 1 |
| Next quarter (ends Dec 2026) | $2.71 | $1.67 | +62.3% | $66.0M | 1 |
| Current fiscal year (ends Mar 2027) | $9.95 | $5.39 | +84.6% | $254.4M | 1 |
| Next fiscal year (ends Mar 2028) | $10.27 | $0.00 | — | $270.9M | 1 |
Key Statistics (as of October 24, 2026 at 03:02 UTC)
| Price | USD 128.66 |
|---|---|
| Change | ▼ 0.34% (down) |
| Previous Close | USD 128.66 |
| Open | USD 128.66 |
| Day Range | USD 125.14 – 129.62 |
| 52-Week Range | USD 69.51 – 144.35 |
| Volume | 88,253 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (MLAB)
Nexqual's technical model rates MLAB "BUY" based on 4 bullish and 1 bearish signals across 127 daily candles, as of October 24, 2026 at 03:02 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 52.2 (neutral) |
| vs SMA50 | Above (USD 126.7) |
| MACD | 0.08 (positive) |
Earnings (MLAB)
| Next Earnings Date | 2026-11-09 |
|---|---|
| EPS Estimate | USD 2.24 |
| Revenue Estimate | $62.20M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.3 vs est 2.55 ▼ miss |
| 2026-03-31 | USD 1.83 vs est 1.39 ▲ beat |
| 2025-12-31 | USD 1.76 vs est 1.47 ▲ beat |
| 2025-09-30 | USD 2.11 vs est 1.56 ▲ beat |
Source: Nexqual, October 24, 2026 at 03:02 UTC.
Financials & Fundamentals (MLAB)
| Total Revenue | $249.72M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +1.00% |
| Gross Margin | +64.21% |
| Operating Margin | +11.69% |
| Profit Margin | +1.92% |
| ROE | +2.66% |
| Debt / Equity | 0.85 |
| Current Ratio | 1.79 |
| Total Cash | $32.24M |
| Total Debt | $161.35M |
Source: Nexqual, October 24, 2026 at 03:02 UTC.
Ownership (MLAB)
| Insider Ownership | +5.62% |
|---|---|
| Institutional Ownership | +100.64% |
| Shares Outstanding | 5.60M |
| Float | 4.95M |
| Short % of Float | +8.22% |
Source: Nexqual, October 24, 2026 at 03:02 UTC.
From Mesa Laboratories, Inc.'s Latest SEC 10-K Filing (filed 2026-06-03)
Key Strengths & Strategy (as disclosed to the SEC)
- We rely upon trade secrets, technical know-how and continuing technological innovation to develop and maintain our proprietary positions.
Legal & Regulatory Risks (Item 1A, quoted)
- Changes in trade policies, tariffs, or industrial policies may increase our costs, disrupt our supply chain, or adversely affect demand for our products.
- Evolving cybersecurity regulations, including the European Union's Cyber Resilience Act, may increase our compliance costs and require changes to our products and processes.
- The interpretation and implementation of the CRA and other evolving cybersecurity regulations continue to develop, and regulatory expectations may change over time.
- Regulatory requirements govern not only the claims that may be made about approved products, but also whether changes to those products require additional regulatory review or clearance.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| UTMD | Utah Medical Products, Inc. | USD 74.23 | ▼ 1.11% |
| WINA | Winmark Corporation | USD 279.71 | ▼ 2.19% |
| OFLX | Omega Flex, Inc. | USD 24.7 | ▼ 0.56% |
| CASS | Cass Information Systems, Inc | USD 54.83 | ▼ 4.92% |
| PFIS | Peoples Financial Services Corp | USD 70.68 | ▼ 0.35% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 03:02 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt